{"id":823527,"date":"2025-03-10T08:22:19","date_gmt":"2025-03-10T12:22:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/"},"modified":"2025-03-10T08:22:19","modified_gmt":"2025-03-10T12:22:19","slug":"insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/","title":{"rendered":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">BRIDGEWATER, N.J.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">March 10, 2025<\/span><\/span> \/PRNewswire\/ &#8212; Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed&#8217;s Compensation Committee and made as a material inducement to each employee&#8217;s entry into employment with the Company.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg\" title=\"Insmed-Logo-Purple (PRNewsfoto\/Insmed Incorporated)\" alt=\"Insmed-Logo-Purple (PRNewsfoto\/Insmed Incorporated)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>In connection with the commencement of their employment, the employees received options on <span class=\"xn-chron\">March 7, 2025<\/span> to purchase an aggregate 47,960 shares of Insmed common stock at an exercise price of <span class=\"xn-money\">$74.89<\/span> per share, the closing trading price on the Nasdaq Global Select Market on the date of grant.<\/p>\n<p>The options have a 10-year term and a four-year vesting schedule, with 25% of the shares subject to the option vesting on the first anniversary of the relevant grant date and 12.5% of the shares subject to the option vesting every six months thereafter through the fourth anniversary of the relevant grant date, subject to the relevant employee&#8217;s continued service with Insmed on the applicable vesting date.<\/p>\n<p>\n        <b>About<\/b>\u00a0<b>Insmed<\/b><\/p>\n<p>Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed&#8217;s most advanced programs are in pulmonary and in\ufb02ammatory conditions, including a therapy approved in <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Japan<\/span> to treat a chronic, debilitating lung disease. The Company&#8217;s early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.<\/p>\n<p>Headquartered in\u00a0Bridgewater, <span class=\"xn-location\">New Jersey<\/span>, Insmed has offices and research locations throughout <span class=\"xn-location\">the United States<\/span>, <span class=\"xn-location\">Europe<\/span>, and <span class=\"xn-location\">Japan<\/span>. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 <i>Science <\/i>Top Employer. Visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4377008-1&amp;h=1180014815&amp;u=http%3A%2F%2Fwww.insmed.com%2F&amp;a=www.insmed.com\" target=\"_blank\" rel=\"nofollow\">www.insmed.com<\/a> to learn more.<\/p>\n<p>\n        <b>Contact:<\/b>\n      <\/p>\n<p>Investors:<\/p>\n<p>\n        <span class=\"xn-person\">Bryan Dunn<\/span><br \/>\n        <br \/>Vice President, Investor Relations<br \/>(646) 812-4030<br \/><u><a href=\"mailto:bryan.dunn@insmed.com\" target=\"_blank\" rel=\"nofollow\">bryan.dunn@insmed.com<\/a><\/u><\/p>\n<p>Michael V.\u00a0Morabito, Ph.D.<br \/>Director, Investor Relations<br \/>(917) 936-8430<br \/><a href=\"mailto:michael.morabito@insmed.com\" target=\"_blank\" rel=\"nofollow\">michael.morabito@insmed.com<\/a><\/p>\n<p>\n        <span class=\"xn-person\">Gianna De Palma<\/span><br \/>\n        <br \/>Manager, Investor Relations<br \/>(848) 360-1281<br \/><a href=\"mailto:gianna.depalma@insmed.com\" target=\"_blank\" rel=\"nofollow\">gianna.depalma@insmed.com<\/a><\/p>\n<p>Media:<br \/><span class=\"xn-person\">Mandy Fahey<\/span><br \/>Vice President, Corporate Communications<br \/>(732) 718-3621<br \/><a href=\"mailto:amanda.fahey@insmed.com\" target=\"_blank\" rel=\"nofollow\">amanda.fahey@insmed.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY34532&amp;sd=2025-03-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302396205.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302396205.html<\/a><\/p>\n<p>SOURCE  Insmed Incorporated<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY34532&amp;Transmission_Id=202503100800PR_NEWS_USPR_____NY34532&amp;DateId=20250310\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire BRIDGEWATER, N.J. , March 10, 2025 \/PRNewswire\/ &#8212; Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed&#8217;s Compensation Committee and made as a material inducement to each employee&#8217;s entry into employment with the Company. In connection with the commencement of their employment, the employees received options on March 7, 2025 to purchase an aggregate 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, the closing trading price on the Nasdaq Global Select Market &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-823527","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BRIDGEWATER, N.J. , March 10, 2025 \/PRNewswire\/ &#8212; Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed&#8217;s Compensation Committee and made as a material inducement to each employee&#8217;s entry into employment with the Company. In connection with the commencement of their employment, the employees received options on March 7, 2025 to purchase an aggregate 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, the closing trading price on the Nasdaq Global Select Market &hellip; Continue reading &quot;Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-10T12:22:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\",\"datePublished\":\"2025-03-10T12:22:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/\"},\"wordCount\":422,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2544698\\\/Insmed_Incorporated_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/\",\"name\":\"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2544698\\\/Insmed_Incorporated_Logo.jpg\",\"datePublished\":\"2025-03-10T12:22:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2544698\\\/Insmed_Incorporated_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2544698\\\/Insmed_Incorporated_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/","og_locale":"en_US","og_type":"article","og_title":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PR Newswire BRIDGEWATER, N.J. , March 10, 2025 \/PRNewswire\/ &#8212; Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Insmed&#8217;s Compensation Committee and made as a material inducement to each employee&#8217;s entry into employment with the Company. In connection with the commencement of their employment, the employees received options on March 7, 2025 to purchase an aggregate 47,960 shares of Insmed common stock at an exercise price of $74.89 per share, the closing trading price on the Nasdaq Global Select Market &hellip; Continue reading \"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/","og_site_name":"Market Newsdesk","article_published_time":"2025-03-10T12:22:19+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","datePublished":"2025-03-10T12:22:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/"},"wordCount":422,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/","name":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg","datePublished":"2025-03-10T12:22:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2544698\/Insmed_Incorporated_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/insmed-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-22\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=823527"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/823527\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=823527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=823527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=823527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}